Table 1.

Summary of the complex structure of Aβ-antibodies

PDB code	antigen	antibody	epitope	paratope	refs
2IPU	Aβ(1–8)peptide DAEFRHDS	Fabs of PFA1	DAEFRHDS	WWDDD	[38]
2R0W	Aβ(1–8)peptide DAEFRHDS	Fabs of PFA2	DAEFRHDS	WWDDD	[38]
2R0Z	GRIP1	Fabs of PFA1	AKFRHD	WWDDD	[38]
2IPT	N/A	PFA1 Fab	N/A	N/A	[38]
2IQ9	N/A	PFA2 FAB fragment, triclinic apo form	N/A	N/A	[38]
2IQA	N/A	PFA2 FAB fragment, monoclinic apo form	N/A	N/A	[38]
3BAE	Aβ(1–28)	WO2	Aβ(2–8)		[39]
3BKC	N/A	WO2 Fab (Form B)	N/A	N/A	[39]
3BKM	N/A	WO2 Fab (Form A)	N/A	N/A	[39]
3BKJ	Aβ (1–16)	WO2 Fab	Aβ(2–8)		[39]
3EYS	pyro-Glu3-A pEFRHDS	PFA1			[44]
3EYS	Ror2 REEFRHEA	PFA1			[44]
3IFO	Aβ 1–7	10D5 Fabs	3EFRHD7		[40]
3IFL	Aβ 1–7	12A11 Fabs	3EFRHD7		[40]
3IFN	Aβ 1–40	12A11 Fabs	3EFRHD7		[40]
3IFP	Aβ 1–7	12B4 Fabs	3EFRHD7		[40]
3LN9	Amyloid Fibril	B10	?	positively charged residues of CDRs1–3	[47]
4OJF	Aβ 1–8	3D6 (Bapineuzumab)	1DAEFR5	L1 24KSSQSLLDSDGKTYLN34	[48]
				L2 50LVSKLDS56
				L3 89WQGTHFPRT97
				H1 26GFTFSNYGMS35
				H2 50SIRSGGGRTYYSDNVKG65
				H3 95YDHYSGSSDY102
4HIX	Aβ 1–40	Bapineuzumab	1DAEFRH6		[48]
4IFO	IDE	Fab(IDE)	K324/Y325/402/459/R 460/D462/E465/	Y54/Y55/102/Y114/S108/109/Y1 12/Y110	[79]
3MCL	N/A	C706 Fab	N/A	N/A	[80]
3O11	N/A	C706 Fab	N/A	N/A	[80]
3TPK	N/A	KW1			[46]
3U0T	Aβ 40	Ponezumab	Aβ30–40		[53]
4M1C	IDE/ Aβ16–20 complex	Fab
4ONF	Aβ 1–7	3D6	1DAEFRHD7		[49]
4ONG	Aβ 1–40	3D6	1DAEFRHD7		[49]
5CSZ	Aβ 1–11	Gantenerumab			[45]
4XXD	Aβ 12–28	solanezumab Fab	Aβ 16–26		[51]